Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 25 2025
0mins
Source: Globenewswire
Merger Announcement: Rafael Holdings, Inc. and Cyclo Therapeutics, Inc. have completed their business combination after receiving shareholder approval, with Rafael issuing shares representing approximately 22% of the combined company to Cyclo's shareholders.
Clinical Development Focus: Rafael Holdings has identified Trappsol® Cyclo™ as its lead clinical asset for treating Niemann-Pick Disease Type C1, with an ongoing Phase 3 trial and anticipation for interim analysis results in mid-2025.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
